Plk1 depletion in nontransformed diploid cells activates the DNA-damage checkpoint (original) (raw)

• Ando K, Ozaki T, Yamamoto H, Furuya K, Hosoda M, Hayashi S et al. (2004). Polo-like kinase 1 (Plk1) inhibits p53 function by physical interaction and phosphorylation. J Biol Chem 279: 25549–25561.
  Article CAS Google Scholar
• Angelis KJ, Dusinska M, Collins AR . (1999). Single cell gel electrophoresis: detection of DNA damage at different levels of sensitivity. Electrophoresis 20: 2133–2138.
  Article CAS Google Scholar
• Barr FA, Sillje HH, Nigg EA . (2004). Polo-like kinases and the orchestration of cell division. Nat Rev Mol Cell Biol 5: 429–440.
  Article CAS Google Scholar
• Bodnar AG, Ouellette M, Frolkis M, Holt SE, Chiu CP, Morin GB et al. (1998). Extension of life-span by introduction of telomerase into normal human cells. Science 279: 349–352.
  Article CAS Google Scholar
• Castedo M, Perfettini J-L, Roumier T, Yakushijin K, Horne D, Medema R et al. (2004). The cell cycle checkpoint kinase Chk2 is a negative regulator of mitotic catastrophe. Oncogene 23: 4353–4361.
  Article CAS Google Scholar
• Eckerdt F, Yuan J, Strebhardt K . (2005). Polo-like kinases and oncogenesis. Oncogene 24: 267–276.
  Article CAS Google Scholar
• Galy A, Neron B, Planque N, Saule S, Eychene A . (2002). Activated MAPK/ERK kinase (MEK-1) induces transdifferentiation of pigmented epithelium into neural retina. Dev Biol 248: 251–264.
  Article CAS Google Scholar
• Gerdes J, Lemke H, Baisch H, Wacker HH, Schwab U, Stein H . (1984). Cell cycle analysis of a cell proliferation-associated human nuclear antigen defined by the monoclonal antibody Ki-67. J Immunol 133: 1710–1715.
  CAS PubMed Google Scholar
• Gumireddy K, Reddy MV, Cosenza SC, Boominathan R, Baker SJ, Papathi N et al. (2005). ON01910, a non-ATP-competitive small molecule inhibitor of Plk1, is a potent anticancer agent. Cancer Cell 7: 275–286.
  Article CAS Google Scholar
• Hardy CF, Pautz A . (1996). A novel role for Cdc5p in DNA replication. Mol Cell Biol 16: 6775–6782.
  Article CAS Google Scholar
• Jiang XR, Jimenez G, Chang E, Frolkis M, Kusler B, Sage M et al. (1999). Telomerase expression in human somatic cells does not induce changes associated with a transformed phenotype. Nat Genet 21: 111–114.
  Article CAS Google Scholar
• Knecht R, Elez R, Oechler M, Solbach C, von Ilberg C, Strebhardt K . (1999). Prognostic significance of polo-like kinase (PLK) expression in squamous cell carcinomas of the head and neck. Cancer Res 59: 2794–2797.
  CAS PubMed Google Scholar
• Knecht R, Oberhauser C, Strebhardt K . (2000). PLK (polo-like kinase), a new prognostic marker for oropharyngeal carcinomas. Int J Cancer 89: 535–536.
  Article CAS Google Scholar
• Liu X, Erikson RL . (2003). Polo-like kinase (Plk)1 depletion induces apoptosis in cancer cells. Proc Natl Acad Sci USA 100: 5789–5794.
  Article CAS Google Scholar
• Liu X, Lei M, Erikson RL . (2006). Normal cells, but not cancer cells, survive severe Plk1 depletion. Mol Cell Biol 26: 2093–2108.
  Article Google Scholar
• Mamely I, van Vugt MA, Smits VA, Semple JI, Lemmens B, Perrakis A et al. (2006). Polo-like kinase-1 controls proteasome-dependent degradation of Claspin during checkpoint recovery. Curr Biol 16: 1950–1955.
  Article CAS Google Scholar
• Rak DJ, Hardy KM, Jaffe GJ, McKay BS . (2006). Ca++- switch induction of RPE differentiation. Exp Eye Res 82: 648–656.
  Article CAS Google Scholar
• Smits VA, Klompmaker R, Arnaud L, Rijksen G, Nigg EA, Medema RH . (2000). Polo-like kinase-1 is a target of the DNA damage checkpoint. Nat Cell Biol 2: 672–676.
  Article CAS Google Scholar
• Soule HD, Maloney TM, Wolman SR, Peterson Jr WD, Brenz R, McGrath CM et al. (1990). Isolation and characterization of a spontaneously immortalized human breast epithelial cell line, MCF-10. Cancer Res 50: 6075–6086.
  CAS PubMed Google Scholar
• Spankuch B, Matthess Y, Knecht R, Zimmer B, Kaufmann M, Strebhardt K . (2004). Cancer inhibition in nude mice after systemic application of U6 promoter-driven short hairpin RNAs against PLK1. J Natl Cancer Inst 96: 862–872.
  Article Google Scholar
• Steegmaier M, Hoffmann M, Baum A, Lenart P, Petronczki M, Krssak M et al. (2007). BI 2536, a potent and selective inhibitor of polo-like kinase 1, inhibits tumor growth in vivo. Curr Biol 17: 316–322.
  Article CAS Google Scholar
• Strebhardt K, Kneisel L, Linhart C, Bernd A, Kaufmann R . (2000). Prognostic value of pololike kinase expression in melanomas. JAMA 283: 479–480.
  Article CAS Google Scholar
• Strebhardt K, Ullrich A . (2006). Targeting polo-like kinase 1 for cancer therapy. Nat Rev Cancer 6: 321–330.
  Article CAS Google Scholar
• Takai N, Hamanaka R, Yoshimatsu J, Miyakawa I . (2005). Polo-like kinases (Plks) and cancer. Oncogene 24: 287–291.
  Article CAS Google Scholar
• Tsvetkov L, Stern DF . (2005). Interaction of chromatin-associated Plk1 and Mcm7. J Biol Chem 280: 11943–11947.
  Article CAS Google Scholar
• Tsvetkov L, Xu X, Li J, Stern DF . (2003). Polo-like kinase 1 and Chk2 interact and co-localize to centrosomes and the midbody. J Biol Chem 278: 8468–8475.
  Article CAS Google Scholar
• Weinstein IB, Joe AK . (2006). Mechanisms of disease: Oncogene addiction—a rationale for molecular targeting in cancer therapy. Nat Clin Pract Oncol 3: 448–457.
  Article CAS Google Scholar
• Winkles JA, Alberts GF . (2005). Differential regulation of polo-like kinase 1, 2, 3, and 4 gene expression in mammalian cells and tissues. Oncogene 24: 260–266.
  Article CAS Google Scholar
• Wolf G, Elez R, Doermer A, Holtrich U, Ackermann H, Stutte HJ et al. (1997). Prognostic significance of polo-like kinase (PLK) expression in non-small cell lung cancer. Oncogene 14: 543–549.
  Article CAS Google Scholar